What this is
- How it works
- How it works isn't classified yet
- Tested for
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs), Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
- Main trialPhase 1
- “This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy”In the company’s words, NCT04603001 on ClinicalTrials.gov
Other drugs for Acute Myeloid Leukemia (AML)
- Pivekimab SunirineAbbVie · Phase 2/3
- QTX-2101Quetzal Therapeutics · Phase 3
- ZiftomenibKura Oncology, Inc. · Phase 3
- QuizartinibDaiichi Sankyo · Phase 3
- MocravimodPriothera SAS · Phase 3
- ATOSDK Therapeutics, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 3 Jul 2023 | Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | |
| Phase 1Active, not recruiting | 17 Jul 2023 | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | |
| Phase 1Completed | 4 Aug 2021 | A Study of LY3410738 in Healthy Adult Participants | |
| Phase 1Terminated | 12 Apr 2022 | Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants | |
| Phase 1Completed | 28 Apr 2022 | A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026